Globus Medical Inc (GMED) reports a 61% annual revenue increase and outlines strategic plans following the Nevro acquisition.

Welcome to the Globus Medical's fourth quarter and full year 2024 earnings call. At this time, all lines will be on mute, and ...

In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price ...

For the quarter ended December 2024, Globus Medical (GMED) reported revenue of $657.29 million, up 6.6% over the same period last year. EPS came in at $0.84, compared to $0.60 in the year-ago quarter.

Medical technologies specialist Globus Medical (NYSE:GMED) reported impressive results for the fourth quarter of 2024 on ...

AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ...

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...

StockNews.com upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a buy rating in a research ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

State of Alaska Department of Revenue reduced its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.2% ...